Kornimate/medical-research-clean huggingface dataset:
an algorithm for intra-operative goal-directed haemodynamic management in non-cardiac surgery

Conditions: Fracture of Surgical Neck of Humerus; Colonic Tumor; Stage IIIB Ovarian Carcinoma; Neoplasm of Head of Pancreas

Summary: a systematic literature search a goal-directed haemodynamic algorithm was created. the hypothesis of this study was that the goal-directed haemodynamic algorithm is feasible and can improve clinical outcome.

after a systematic literature search a goal-directed haemodynamic algorithm was created. the algorithm was adapted to international standards and consensus was reached through a modified delphi method at international meetings. the feasibility of using the algorithm for intraoperative haemodynamic management was tested and the resultant clinical data analyzed retrospectively for several types of surgery with the hypothesis that the goal-directed haemodynamic algorithm is feasible in the clinical setting and can improve clinical outcome.

Eligibility criteria:
inclusion criteria: * patients undergoing a surgical repair of hip fractures, open right hemicolectomy and extended hemicolectomy, radical tumor debulking in primary ovarian cancer or a pylorus-preserving pancreatic head resection at the charité - university medicine berlin, campus virchow clinic * 18 years and older exclusion criteria: * emergency procedures

Keywords: haemodynamic goal-directed therapy surgery anaesthesia
adjunctive periodontal treatment with coenzyme q10 in association with probiotics for pregnant women

Conditions: Periodontal Diseases; Pregnancy Related

Summary: the aim of the study is to assess if probiotic supplementation can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients.

the aim of the study is to assess if probiotic supplementation can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. patients' enrollment will be conducted according to inclusion criteria. at the first visit, periodontal parameters will be recorded: plaque index (pi), recession (r) bleeding on probing (bop), modified marginal gingival index (mmgi), papillary marginal gingival (pmgi), plaque control record ( pcr %), approximal plaque index (api), clinical attachment loss (cal) and probing pocket depth (ppd). professional debridement will be conducted with piezoelectric instrumentation and air-flow administration with glycine powders. subsequently, patients will be randomly divided into two groups: * the probiotic group, in which patients will undergo daily probiotic supplementation in addition to the standard treatment * the control group, in which patients will undergo standard treatment professional debridement will be repeated every 3 months. periodontal index evaluation will be conducted at the baseline (t0), after 1 month (t1), after 3 months (t2), and after 6 months (t3).

Eligibility criteria:
inclusion criteria: * women at the 4th month of pregnancy exclusion criteria: * presence of cardiac pacemaker * neurological and psychiatric diseases * patients taking bisphosphonates during the previous 12 months from the beginning of the study * patients undergoing anticancer therapy. * patients with poor compliance.
cool-trial: outcome with invasive and non-invasive cooling after cardiac arrest

Conditions: Cardiac Arrest; Hypothermia

Summary: sudden cardiac arrest (sca) remains one of the major leading causes of death. cognitive deficits are common in survivors of sca. postresuscitative mild induced hypothermia (mih) lowers mortality and reduces neurologic damage after cardiac arrest. the investigators evaluated the efficacy and side effects of therapeutic hypothermia in an unselected group of patients after sca.

consecutive patients with restoration of spontaneous circulation (rosc) after resuscitation due to out-of-hospital sca, admitted to our intensive care unit, underwent mih. hypothermia was induced by infusion of cold saline and whole-body-cooling methods (electronic randomization: invasive coolgard or non-invasive arcticsun). the core body temperature was operated at 32 to 34 °c over a period of 24 hours followed by active rewarming. neurological status was evaluated at hospital discharge and 6 months after discharge using the pittsburgh cerebral performance category (cpc). blood samples of neuron-specific enolase (nse) were collected during 72 hours.

Eligibility criteria:
inclusion criteria: * rosc after sca due to vf/vt or pea/asystolia * gcs 3 exclusion criteria: * non-cardiac sca * pregnancy * unstable circulation instead of high-dose inotropics * life-expectancy reducing concomitant illness

Keywords: sudden cardiac arrest hypothermia outcome, neurological coolgard arcticsun
polygenic risk score to predict weight loss intervention in children with obesity

Conditions: Obesity; Children

Summary: children with obesity are prone to suffering from metabolic diseases, which undoubtedly increases the burden of public health. since obesity is a multiple gene disease, a comprehensive approach using polygenic risk scores (prs), rather than individual genetic variant, may be a more appropriate method. the aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes.

the investigators hypothesize that obesity gene variants can predict the efficacy of weight loss intervention in obese children. the aim of the study was to establish a polygenic risk score model to assess differences to assess differences in weight loss treatment outcomes. the investigators will also analyze whether these gene variants have an effect on obesity comorbidities (hypertension, hyperlipidemia, non-alcoholic fatty liver disease, type 2 diabetes, obstructive sleep apnea, polycystic ovary syndrome, etc.). for participants with non-simple obesity, the investigators will collect their complete family history, and perform whole exome sequencing to identify possible rare disease-causing genes. the experimental design is as follows: obese children and adolescent subjects will undergo a 6-month weight loss intervention program and be followed for 12-18 months. the investigators will analyze obesity and fatty liver-related genes in these adolescents using next-generation gene sequencing and/or gene chips, perform polygenic risk score analysis, and use an additive model to total the number of variant loci weighted by effect size. whole exome gene sequencing refers to the human dna map (hg19), and sanger sequencing will be used to confirm the correctness of the variant site.

Eligibility criteria:
inclusion criteria: * age \<18 years old * obesity definition: bmi \> 95% according to the age- and gender-specific standard by national health institute in taiwan * willing to give written informed consent exclusion criteria: * alcohol consumption * major systemic diseases, including cardiopulmonary disease, renal failure, cancer, and major psychotic disorder

Keywords: whole exome sequencing polygenic risk score weight loss
sungurtekin technique vs. closed lateral internal sphincterotomy technique

Conditions: Anal Fissure

Summary: background: currently, the lateral internal sphincterotomy is the treatment of choice for a chronic anal fissure. however, the length of the internal sphincter incision varies, due to lack of standardization. insufficient length increases the risk of recurrence. objective: to compare a new ultra-modified internal sphincterotomy technique to the closed lateral sphincterotomy for treating chronic anal fissures, based on internal anal sphincter function and postoperative complications. design: prospective, randomized, controlled trial (block randomization method) setting: pamukkale university hospital in denizli-turkey participants: 200 patients with chronic anal fissures intervention: patients were randomly assigned to receive either sungurtekin technique (n = 100; ultra-modified group), or the closed lateral internal sphincterotomy (n = 100; closed-lateral group). follow-up was 2 years. main outcome measures: the primary outcome was chronic anal fissure healing. the secondary outcomes were complications, visual analog scale pain scores, sphincter pressures, and incontinence scores.

although the lateral internal sphincterotomy is the treatment of choice for caf, it has several drawbacks. first, the lower portion of the internal sphincter is nested in the lowermost part of the anus. thus, an incision from the fissure base up to the dentate line removes support to the inner sphincter structure on the incision site. in our opinion; this is the main cause of different levels of incontinence developing in the postoperative period. second, the internal sphincter muscle is shorter in women than in men. therefore, women are at higher risk of postoperative anal incontinence than men. third, because the lateral internal sphincterotomy is not standardized, the length of the internal sphincter incision varies, depending on the surgeon's discretion and competency. fourth, an incision that is too short increases in the risk of recurrence. the investigators believe that this observation could be explained by the fact that the length of the incision required for a lateral internal sphincterotomy procedure has not been standardized

Eligibility criteria:
inclusion criteria: patients with cafs that had failed conservative therapy and required surgical treatment - exclusion criteria: * patients who have a low resting anal pressure in manometric study (lower than 40 mmhg) * recurrent anal fissure * fissure location other than the posterior anal canal * fissure due to inflammatory bowel or infectious disease * acute anal fissure, * fissure due to chronic diarrhea or anal stenosis * anorectal malignancy * patients undergone pelvic radiotherapy * pregnancy * patients with history of diabetes, neurological disease and spinal cord lesions * previous episiotomy history * painless fissures

Keywords: fissure-in-ano sphincterotomy i̇ncontinence surgical technique
efficacy and safety of oral rifaximin in patients with active microscopic colitis

Conditions: Microscopic Colitis

Summary: this is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

this is an open-label single-arm trial to evaluate the efficacy of rifaximin in patients with active microscopic colitis (mc). 10 subjects will be asked to take 500mg rifaximin three times per day for 4 weeks. the primary endpoints will be histologic response and clinical remission (less than 3 stools per day and less than 1 watery stool per day within the prior 7 days. the secondary endpoint will be change of the mc disease activity index (mcdai).

Eligibility criteria:
inclusion criteria: * collagenous colitis (cc) or lymphocytic colitis (lc) diagnosed on colon biopsies reviewed by 2 separate pathologists * cc will be defined histologically to be the following: thickness of the collagenous subepithelial table \>10 micrometer using an ocular micrometer, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, lack of crypt architectural distortion, and regenerative-appearing changes in the surface and/or crypt epithelium * lc will be defined histologically to be the following: intraepithelial lymphocytes \>20 per 100 epithelial cells in the subjective area of highest lymphocyte density, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, and regenerative-appearing changes in the surface and/or crypt epithelium * subjects in active flare, defined as \>3 watery/loose stools per day on \>4 / 7 days over \>4 weeks in the past 3 months. exclusion criteria: -

Keywords: microscopic colitis
a study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for unresectable, locally advanced/metastatic non-small cell lung cancer with her2 mutations

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Summary: destiny-lung04 will investigate the efficacy and safety of trastuzumab deruxtecan (t-dxd) versus standard of care (soc) as first-line treatment of non-small cell lung cancer (nsclc) with her2 exon 19 or 20 mutations

eligible participants will be those diagnosed with unresectable, locally advanced or metastatic histologically documented non-squamous nsclc with her2 exons 19 or 20 mutations and who are treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease. the study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan as first-line treatment of non-small cell lung cancer (nsclc) as compared with standard of care treatment (investigator's choice of cisplatin or carboplatin + pembrolizumab + pemetrexed). this study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse or simply to live longer, compared to patients receiving standard of care treatment. this study is also looking to see how the treatment and the cancer affects patients' quality of life.

Eligibility criteria:
inclusion criteria: * participants at least 18 years of age * locally advanced and unresectable nsclc, not amenable to curative therapy, or metastatic disease * histologically documented non-squamous nsclc with her2 mutation in exons 19 or 20 by tissue ngs or ctdna * treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease * left ventricular ejection fraction (lvef) ≥ 50% * measurable disease assessed by investigator based on recist 1.1 * protocol-defined adequate organ function including cardiac, renal, hepatic function * ecog 0-1 * having tumour tissue available for central testing exclusion criteria: * tumors with targetable alterations to egfr (or other targetable mutations including but not limited to alk, if routinely tested as a targetable alteration with approved available therapy) * any untreated brain metastases, including asymptomatic or clinically inactive brain metastases * active autoimmune or inflammatory disorders * medical history of myocardial infarction within 6 months prior to randomization * history of non-infectious pneumonitis/ild, current or suspected ild * lung-specific intercurrent clinical significant severe illness * contraindication to platinum-based doublet chemotherapy or pembrolizumab

Keywords: ds-8201a her2 exon 19 or 20 mutations erbb2 gene (coding for the her2 protein) t-dxd trastuzumab deruxtecan locally advanced and unresectable non-squamous nsclc metastatic non-squamous nsclc non-small cell lung cancer
vaping adverse lung and heart events cohort

Conditions: Vaping; Electronic Cigarette Use

Summary: this prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.

daily vaping device users will be recruited in the quebec city metropolitan area. subjects will be asked to perform pulmonary function tests (spirometry, oscillometry, plethysmography, methacholine provocation) every 6 months for a 5-year follow up. subjects will also answer a questionnaire assessing their vaping, tobacco and cannabis smoking habits, as well as their perceived respiratory symptoms. blood draws and sputum inductions will be performed for cell counts and to measure inflammation markers.

Eligibility criteria:
inclusion criteria: * age 18 years or older * daily electronic cigarette user * no respiratory infection in the 4 weeks before a visit exclusion criteria: * women who are pregnant or breast-feeding.

Keywords: vaping vape electronic cigarette electronic and vaping acute lung injury evali
hypertonic saline therapy in ambulatory heart failure unit.

Conditions: Heart Failure

Summary: the purpose of this study is to compare intravenous furosemide (125 to 250 mg), isolated or in combination with hypertonic saline solution (2.6% to 3.4%) in the outpatient heart failure patient. the hypothesis is that the combination therapy will increase the diuresis volume at 3 hours and improve congestion parameters at 7 days.

this is a randomized, double-blind, multicenter study of all consecutive patients with decompensated heart failure and signs of volume overload who do not require hospital admission but require intravenous diuretic for relief of congestion. patients meeting the inclusion criteria, with prior informed consent, will be randomized to treatment with furosemide with hypertonic saline versus isolated furosemide (control group). complete clinical evaluation, echocardiography, and blood and urinary tests will be performed before the treatment. after 3 hours, diuresis volume, weight and urinary parameters will be evaluated. efficacy and safety visits will be performed at 7 and 30 days.

Eligibility criteria:
inclusion criteria: * previous heart failure diagnosis (according to current european guidelines) * stable treatment in the previous 4 weeks (except diuretic). * home oral treatment of ≥80 mg of furosemide/day or equivalent (40 mg furosemide = 20 mg of torasemide). * transthoracic echocardiogram performed in the last year. * congestive signs.the presence of two of the following congestion criteria will be required: jugular pressure\> 10 cm, lower limb edema, ascites, or pleural effusion * elevation of natriuretic peptides (ntprobnp\> 1000 pg / ml or b-type natriuretic peptide\> 250 pg / ml) performed in a previous period of no more than 24 hours. * need for intravenous diuretic therapy to relieve congestion according to the responsible physician. exclusion criteria: * hospital admission criteria in the opinion of the responsible physician. * systolic blood pressure \ 180 mmhg. * heart rate\> 150 bpm or \< 40 bpm * basal oxygen saturation less than 90%. * cardiogenic shock. * acute pulmonary edema. * clinically significant arrhythmia. * acute myocardial ischemia. * patients in hemodialysis or peritoneal dialysis program. * serum sodium \ 145 milliequivalent / l. * serum potassium \< 3.5 milliequivalent/ l. * hemoglobin \< 9 g / dl * acute coronary syndrome or cardiological procedure in the previous 2 weeks. * severe uncorrected valve disease except tricuspid regurgitation. * moderate or severe dementia, active delirium or psychiatric problems. * patients in whom cardiac surgery or device implantation is planned in the following 30 days. * pregnancy or breastfeeding. * inability to give informed consent in the absence of a legal officer. * patients on tolvaptan. * inability to collect the urine.

Keywords: hypertonic saline solution outpatient heart failure
hens hatching hope

Conditions: Malnutrition, Child

Summary: the study is a prospective community-cluster non-randomized trial that will evaluate the effectiveness of a program that will provide 30-day egg vouchers to mothers of 6 to 24 month-old children living in rural areas of intibucá, honduras.


Eligibility criteria:
inclusion criteria: * healthy children ages 6 to 24 months at the time the study begins * no cerebral palsy, birth defect or condition that may affect their growth or development. * children living in the department of intibucá, honduras exclusion criteria: * children from families that are considering leaving the region within the next 12 months * known egg allergy

Keywords: stunting eggs diarrhea complementary foods
telemonitoring device in managing outpatient care of patients with myelodysplastic syndrome or acute myeloid leukemia after intensive chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome

Summary: this randomized pilot clinical trial studies a home telemonitoring device in managing the care of patients with myelodysplastic syndrome or acute myeloid leukemia after they are discharged from the hospital following chemotherapy. after treatment and hospital discharge, patients typically need extensive care to deal with the side effects of chemotherapy, keep up with medications, and obtain medical assistance. a home telemonitoring device would allow patients to monitor vital signs, symptoms, and use of medications, communicate with healthcare providers, and access educational material. a telemonitoring device may allow patients to be managed more effectively than standard outpatient care after being discharged from the hospital.

primary objectives: i. to determine the feasibility of home telemonitoring for adult patients following intensive induction, re-induction/salvage, or consolidation chemotherapy for myelodysplastic syndrome (mds) or non-acute promyelocytic leukemia (apl) acute myeloid leukemia (aml). secondary objectives: i. to estimate the impact of the telemonitoring intervention on mortality, duration of hospital stay, use of emergency services, visits to primary care physicians and to specialists, home visits, and telephone calls ("health care resource utilization"). ii. to evaluate the telemonitoring procedure in economic terms compared to usual care through a cost-effectiveness analysis. iii. to estimate the impact on the quality of life of study participating. iv. to assess the degree of satisfaction of the patients/caregivers and health care professionals with the telemonitoring intervention. outline: patients are randomized to 1 of 2 arms. arm i (control): patients receive standard outpatient supportive care after completion of chemotherapy. arm ii (intervention): patients receive standard outpatient supportive care as in arm i and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).

Eligibility criteria:
inclusion criteria: * diagnosis of mds or aml other than apl with t(15;17)(q22;q12), (promyelocytic leukemia\[pml\]/retinoic acid receptor \[rar\]), or variants according to the 2008 world health organization (who) classification * patient is currently undergoing aml-like intensive induction, re-induction/salvage, or consolidation chemotherapy, or planned to start such therapy within 1 week * willingness to have close follow-up and treatment at the clinic at the seattle cancer care alliance (scca) or at a local facility; typically, patients will be seen at least 3 times per week as per standard practice, including at least once weekly at the scca * permanent or temporary housing available within a 60 minute (min) commute from the scca * available caregiver * willingness and ability to use the telemonitoring device * provision of written informed consent exclusion criteria: * cognitive impairment